Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04405323 · ClinicalTrials.gov registry record · Phase 1
Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04405323 is a Phase 1 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 16 participants.
The verdict
NCT04405323, a Phase 1 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
A study to learn how a drug (itraconazole) that is known to inhibit a certain enzym in the liver, impacts the body's ability to breakdown Lu AG06466 into breakdown products in healthy men and women. The main breakdown product is Lu AG06988.
Interventions
- DRUG Itraconazole
- DRUG Lu AG06466
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-05-20 |
| Est. Completion | 2020-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04405323
The ClinicalTrials.gov registry entry for NCT04405323 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Itraconazole is the first listed.
NCT04405323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04405323 about?
NCT04405323 is a clinical study titled "Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women". A study to learn how a drug (itraconazole) that is known to inhibit a certain enzym in the liver, impacts the body's ability to breakdown Lu AG06466 into breakdown products in healthy men and women. The main breakdown product is Lu AG06988.
What is the current status of trial NCT04405323?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2020-05-20. Estimated completion is 2020-07-28.
What interventions are being tested in trial NCT04405323?
The interventions under investigation include: Itraconazole (DRUG), Lu AG06466 (DRUG).
Who is sponsoring clinical trial NCT04405323?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.